ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,769.70
-0.11%
S&P ASX All Technology
3,089.10
-0.16%
Brent Oil
84.515
-0.32%
US Dollar vs AUD
1.49885
-0.16%
Bitcoin
65,180.57
0.06%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Xenon Pharmaceuticals Inc (XENE)

  7. Xenon Pharmaceuticals Inc (XENE) News

XENE Xenon Pharmaceuticals Inc

36.25
-0.35 (-0.96%)
19 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Xenon Pharmaceuticals Inc XENE NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
Upgrade Icon
-0.35 -0.96% 36.25 10:00:00
Open Price Low Price High Price Close Price Previous Close
36.71 35.66 36.95 36.25 36.60
more quote information »

Recent News

Date Time Source Heading
13/6/202407:32EDGAR2Form 144 - Report of proposed sale of securities
06/6/202407:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/6/202407:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/6/202407:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/6/202407:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/6/202407:30EDGAR2Form 144 - Report of proposed sale of securities
06/6/202406:22EDGAR2Form S-8 - Securities to be offered to employees in employee..
06/6/202406:12EDGAR2Form 8-K - Current report
06/6/202406:01GLOBEXenon Pharmaceuticals to Present at the Goldman Sachs 45th..
28/5/202422:30GLOBEXenon Pharmaceuticals Presents Data from Phase 2 X-NOVA..
10/5/202406:35EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/5/202406:09EDGAR2Form 8-K - Current report
10/5/202406:01GLOBEXenon Pharmaceuticals Reports First Quarter 2024 Financial..
09/5/202406:01GLOBEXenon Pharmaceuticals to Present at the BofA Securities..
08/5/202406:01GLOBEXenon Pharmaceuticals to Present at the 2024 RBC Capital..
03/5/202406:01GLOBEXenon Pharmaceuticals Announces Conference Call and Webcast..
16/4/202422:30GLOBEXenon Pharmaceuticals Showcases XEN1101 at the American..
05/4/202407:01GLOBEXenon Pharmaceuticals to Present at the 23rd Annual Needham..
13/3/202407:01GLOBEXenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS..
09/3/202410:47EDGAR2Form 144 - Report of proposed sale of securities
09/3/202409:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/3/202409:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/3/202409:27EDGAR2Form 8-K - Current report
08/3/202411:04EDGAR2Form 144 - Report of proposed sale of securities
08/3/202411:03EDGAR2Form 144 - Report of proposed sale of securities
06/3/202408:01GLOBEXenon Pharmaceuticals to Present at Leerink Partners Global..
01/3/202408:10EDGAR2Form 8-K - Current report
01/3/202408:01GLOBEXenon Pharmaceuticals Reports Fourth Quarter and Full Year..
23/2/202408:01GLOBEXenon Pharmaceuticals Announces Conference Call and Webcast..
15/2/202401:12EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
09/1/202400:00GLOBEXenon Pharmaceuticals Outlines Key Milestone Opportunities..
04/1/202400:30GLOBEXenon Pharmaceuticals to Present at the 42nd Annual J.P...
03/1/202408:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/12/202308:16GLOBEXenon Pharmaceuticals Announces Closing of $345.0 Million..
03/12/202304:01GLOBEXenon Pharmaceuticals Provides Updates on Neurology Pipeline..
01/12/202308:18EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
01/12/202308:15EDGAR2Form 8-K - Current report
30/11/202314:51GLOBEXenon Pharmaceuticals Announces Pricing of Upsized $300.0..
30/11/202309:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
30/11/202308:03GLOBEXenon Pharmaceuticals Announces Proposed Public Offering
27/11/202323:03EDGAR2Form 8-K - Current report
27/11/202323:00GLOBEXenon Pharmaceuticals Announces Topline Results from Phase 2..
10/11/202308:06EDGAR2Form 8-K - Current report
10/11/202308:03GLOBEXenon Pharmaceuticals Provides Update on Partnered Program..
09/11/202308:36EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202308:11EDGAR2Form 8-K - Current report
09/11/202308:01GLOBEXenon Pharmaceuticals Reports Third Quarter 2023 Financial..
02/11/202307:01GLOBEXenon Pharmaceuticals Announces Conference Call and Webcast..
10/10/202307:15GLOBEXenon Pharmaceuticals Announces Publication of Results from..
06/10/202323:30GLOBEXenon Pharmaceuticals to Present at Jefferies Inaugural..

Your Recent History

NASDAQ
XENE
Xenon Pharmaceuticals
ASX
JAYN
Jayride
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved